ALTIMMUNE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the October 6th Deadline in the Altimmune Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its Phase 2b MASH trial, leading to significant stock price decline [8]. Allegation Details - The lawsuit claims that Altimmune provided inflated expectations prior to the announcement of the trial results on June 26, 2025, which revealed a failure to achieve statistical significance in the primary endpoint of fibrosis reduction [8]. - The stock price of Altimmune dropped from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [8]. Next Steps - Investors who purchased Altimmune shares between August 10, 2023, and June 25, 2025, and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][8].